News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Epigenetic editors are a gentler form of gene editing

February 24, 2025

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

All Stories

All
News
Press Releases
News

Scribe Therapeutics plans to test cholesterol-lowering epigenetic editing therapy

January 14, 2026

Endpoints

Read Now
News

CRISPR Slashes ‘Bad Cholesterol’ Levels by 95 Percent in Early Results

November 27, 2025

Singularity Hub

Read Now
News

Can AI take the guesswork out of CRISPR?

November 24, 2025

Drug Discovery News

Read Now
News

Can genetic medicine solve cardiovascular disease?

November 20, 2025

Longevity.Technology

Read Now
News

Scribe eyes clinic after CRISPR candidates lower lipids in animals

November 17, 2025

Fierce Biotech

Read Now
News

Epigenetic approach shows durable PCSK9 silencing in primates

October 15, 2025

BioWorld

Read Now
Press release

Scribe Therapeutics Appoints David Parrot as Chief Financial Officer and George Manning as Controller

March 9, 2022

Read Now
Press release

Scribe Therapeutics Raises $100M Series B Financing to Further Develop 'CRISPR by Design' Platform and Pipeline of Breakthrough Genetic Medicines

March 31, 2021

Read Now
Press release

Scribe Therapeutics Co-Founder Jennifer Doudna Receives 2020 Nobel Prize in Chemistry

October 9, 2020

Read Now
Press release

Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines for Neurological Diseases Including ALS

October 6, 2020

Read Now
Press release

Scribe Therapeutics Unveils Fully Integrated Platform for Engineering Breakthrough CRISPR-based Genetic Medicines

October 6, 2020

Read Now

Publications and presentations